

Treatment Naïve

Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6  
**C-SCAPE**


Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

# Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Features

## C-SCAPE Trial

- **Design:** Open-label, phase 2 trial to evaluate the efficacy and safety of elbasvir + grazoprevir + ribavirin versus elbasvir + grazoprevir versus grazoprevir + ribavirin in non-cirrhotic, treatment-naïve patients with GT 2, 4, 5, or 6 chronic hepatitis C infection
- **Entry Criteria**
  - Chronic HCV GT2 (n = 60), GT4 (n = 20), GT5 (n = 8), or GT6 (n = 10)
  - Age 18 years or older
  - No prior HCV treatment
  - HCV RNA  $\geq$ 10,000 IU/mL
  - No evidence of cirrhosis
- **Primary End-Point:** SVR12

# Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Study Design for GT 1



**Abbreviations:** EBR = Elbasvir; GZR = Grazoprevir; RBV = ribavirin

## Drug Dosing

Elbasvir (50 mg) once daily

Grazoprevir (100 mg) once daily

Ribavirin (weight-based and divided bid): 800 to 1400 mg/day

Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

# Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Baseline Characteristics


Baseline Characteristic	Genotype 2		Genotype 4, 5, 6	
	EBR + GZR + RBV (n = 30)	GZR + RBV (n = 30)	EBR + GZR + RBV (n = 19)	EBR-GZR (n = 19)
Mean age, y (range)	47.3	48.3	52.2	52.8
Male sex, %	63.3	56.7	42.1	63.2
Race, %				
White	100	86.7	73.7	68.4
Other	0	13.3	26.3	31.6
HCV Genotype, n				
2	30	26	0	0
4	0	0	10	10
5	0	0	4	4
6	0	0	4	4
1	--	4	--	--
HCV RNA				
≤ 2 million	36.7	36.7	57.9	36.8
>2 million	63.3	63.3	42.1	63.2

\*Excluded from modified intent-to-treat analysis due to discordant genotype

Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

# Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5, or 6 C-SCAPE Study: Results

## C-SCAPE: SVR12 by Genotype and Regimen



Source: Brown A, et al. J Viral Hepat. 2018;25:457-64.

# Elbasvir + Grazoprevir +/- RBV in Treatment-Naïve GT 2, 4, 5 or 6 C-SCAPE Study: Conclusions

**Conclusions:** “These data support the inclusion of participants with genotype 4 or 6 infection in the elbasvir-grazoprevir phase 3 studies. Elbasvir-grazoprevir ± ribavirin was unsatisfactory for participants with genotype 2 or 5 infection.”